Lenstec, Inc.
  • Home
  • About Us
    • Company History
    • Locations
    • Regulatory Registrations
  • Products
    • International >
      • Softec Series IOLs >
        • Softec HD >
          • Technical Specifications
          • Resources
          • Testimonials
        • Softec HDM >
          • Technical Specifications
        • Softec HD3
        • Softec I >
          • Technical Specifications
          • Resources
        • Softec HDY >
          • Technical Specifications
          • Resources
        • Softec HDO >
          • Technical Specifications
          • Resources
      • Softec HP1
      • SBL-2 >
        • Technical Specifications
        • Resources
      • SBL-3 >
        • Technical Specifications
        • Resources
      • Tetraflex HD >
        • Technical Specifications
        • Resources
      • PMMA Lenses
      • Surgical Knives
      • Capsular Tension Rings
      • Instruments/Delivery System >
        • Resources
    • U.S.A. >
      • Softec HD >
        • Technical Specifications
        • Resources
        • Testimonials
      • Softec HDM >
        • Technical Specifications
      • Softec HDO >
        • Technical Specifications
        • Resources
      • Softec I >
        • Technical Specifications
        • Resources
      • Instruments/Delivery System >
        • Resources
    • Instructions for Use
    • VideoTestimonials >
      • Woodcock
      • Tyson
      • Harvey
      • Desai
      • Wortz
      • Matossian
  • News
  • Customers
  • Contact Us

SBL-3 Clinical Data Results Discussion at ASCRS

7/29/2021

 
Drs. Chu, Whitsett, and Loden were speaking of the SBL-3 Clinical Data results during the ASCRS in Las Vegas
Picture
Picture
Picture

Softec HD Lens Implanted in Young Patient  with Soft Cataract

11/17/2020

 
Dr. Justin Spaulding, who implants our Softec HD Lenses, using our Softec HD in a young patient with soft cataracts.

Lenstec Submits SBL3 IOL For Pre-Market Approval

3/19/2020

 
St. Petersburg, FL. March 16, 2020
 
Lenstec Inc. has announced its submission of the SBL- 3 IOL for Pre – Market Approval in the U.S.
The Lenstec SBL - 3 IOL (Segmented Bi-Focal Lens) is an asymmetric multifocal refractive IOL utilizing a 3 diopter add with a transition zone connecting the distance and near segments. It provides patients with near, intermediate and distance vision. In comparison to other available multifocal IOL’s, it shows a reduced occurrence of halos and glare and improved contrast sensitivity.

The SBL 3 has been widely used outside of the United State and has been found to be a valuable option for the refractive lens surgeon.
​
This is an exciting milestone for Lenstec and brings us closer to completing regulatory approval in the U.S. said Lenstec’s VP Sales and Marketing, Gary Lattanzio.
 
Utilizing segmented bi-aspheric optic technology, the SBL-3 has two refracting surfaces to capture light on different parts of the retina for near, intermediate and distance vision.
 
Lenstec’s patented four-point fixation shape design, and 0.25 diopter power increments enable the best Effective Lens Positioning and Visual Outcomes possible.
 
Upon successful FDA approval, the SBL-3 would be the first Segmented Bi – Focal IOL in the U.S. market.                                  
 
About Lenstec
 
Lenstec is a leading designer and manufacturer of intraocular Lenses (IOLs) to treat patients with a range of vision disorders. Founded in 1992, the company is dedicated to advancing possibilities for ophthalmic professionals and their patients worldwide.
 
More information about the SBL-3 and Lenstec’s line of Precision Series IOL’s is available at www.lenstec.com

Softec HDO IOL featured in the Guardian Newspaper by the London Ophthalmology Center

9/25/2019

 
Picture

Lenstec Completes FDA Trials of SBL-3

8/30/2019

 
Lenstec announced that it has completed its FDA trial for the SBL-3 IOL (Segmented Bifocal Lens), an asymmetric multifocal refractive IOL designed to provide patients with superior near, intermediate, and distance vision. It also offers improved contrast sensitivity and minimizes halos and glare (dsyphotopsias) commonly associated with other traditional multifocal-presbyopia correcting IOLs, according to a company news release.
“This is an exciting milestone for Lenstec and brings us closer to completing regulatory approval in the US,” Lenstec’s VP Sales and Marketing Gary Lattanzio said in the news release.
Utilizing segmented bi-aspheric optic technology, the SBL-3 has two refracting surfaces to capture light on different parts of the retina for near and distance vision.
Lenstec’s patented 4-point fixation shape design, and 0.25 diopter power increments enable superior effective lens positioning and visual outcomes.
Upon successful completions of these trials and final FDA approval, the SBL-3 would be the first segmented bifocal IOL in the US market.     
Picture

Lenstec @ ASCRS 2019 Booth & Customer Appreciation Reception!

5/15/2019

 
Picture
Picture
Picture

Lenstec Inc. has announced that it has completed enrollment of the FDA trial for the SBL-3 IOL.

8/29/2018

 
Lenstec Inc. has announced that it has completed enrollment of the FDA trial for the SBL-3 IOL.
​
The Lenstec SBL - 3 IOL (Segmented Bi Focal Lens) is a non-concentric asymmetric multifocal refractive IOL. It provides patients with superior near, intermediate and distance vision. It also improves contrast sensitivity, and minimizes the halos and glare, (dsyphotopsias) commonly associated with other traditional concentric traditional multifocal- presbyopia correcting IOLs.
 
Utilizing segmented bi-aspheric optic technology, the SBL-3 has two refracting surfaces to capture light differently to the retina, for near and distance vision.
 
Lenstec’s patented four - point fixation shape design, and 0.25 diopter power increments enable the best Effective Lens Positioning and Visual Outcomes possible.
 
Upon successful completions of these trials and final FDA approval, the SBL-3 would be the first      Segmented Non-Concentric Bi – Focal IOL in the U.S. market.                                  
 
About Lenstec
 
Lenstec is a leading designer and manufacturer of intraocular Lenses (IOLs) to treat patients with a range of vision disorders. Founded in 1993, the company is dedicated to advancing possibilities for ophthalmic professionals and their patients worldwide.

Custom Vision Upgrade With the Softec HD IOL

5/29/2018

 
Neel R. Desai, MD, explains how the Softec HD IOL (Lenstec) benefits his practice. He describes the outcome-based conversations he has with patients about this lens and shares specific pearls for implanting this lens.​​

​Click on the image below to view the video. 
NOTE: YOU WILL BE REQUIRED TO REGISTER A NEW, FREE EYETUBE ACCOUNT TO VIEW THE VIDEO TO ITS ENTIRETY.

Picture

Lenstec and Oculentis Settle Legal Dispute Over Patents for Bifocal IOLs

3/2/2018

 
Lenstec has stated that it has won its UK patent suit against Oculentis for bifocal IOLs. Oculentis has withdrawn legal proceedings against Lenstec in the UK High Court and made a payment towards Lenstec’s legal costs, according to a Lenstec news release.

Lenstec has agreed not to pursue Oculentis for any additional costs in what Lenstec said was always considered to be a "frivolous lawsuit and without merit." Lenstec’s SBL-3 and SBL-2 IOLs use a patented design which does not infringe on any of Oculentis’ intellectual property.
​
In commenting on the resolution of the legal dispute, Lenstec stated that, “The cessation of the legal proceedings and acknowledgement by Oculentis that Lenstec did not infringe on their patent is very timely. On the one hand, Lenstec is close to completing enrollment in its US clinical trial for the SBL-3 lens, so it is commercially advantageous to us. Secondly, with the growing popularity of the Extended Depth of Focus lens category, it is a great time for us to reconnect with surgeons to reiterate that all of the trifocal and other multifocal lenses remain based on a concentric ring platform, and these are renowned for high levels of dysphotopsias (halos and glare). The bifocal platform is significantly less susceptible to dysphotopsias, leading to happier patients and reliable levels of near and intermediate vision. We look forward to redoubling our efforts in the multifocal category.”

http://eyewiretoday.com/2018/02/23/lenstec-and-oculentis-settle-legal-dispute-over-patents-for-bifocal-iols
​

Lenstec at aSCRS 2017 in Los Angeles

5/12/2017

 
Picture
Picture
Picture
Picture
<<Previous

    Archives

    July 2021
    November 2020
    March 2020
    September 2019
    August 2019
    May 2019
    August 2018
    May 2018
    March 2018
    May 2017
    February 2017
    April 2016
    August 2015
    January 2015
    October 2014
    May 2014
    April 2014
    November 2013
    May 2013
    April 2013
    March 2012

    RSS Feed

World Headquarters

Lenstec, Inc.
1765 Commerce Ave. N.
St. Petersburg, FL 33716 USA
Tel: +1 727-571-2272
Fax: +1 727-571-1792



U.S. CUSTOMER SERVICE:
TEL: 1-866-536-7832
FAX: 1-866-536-3040

​Lenstec Barbados

Lenstec (Barbados) Inc.
Airport Commercial Centre
Pilgrim Road
Christ Church, Barbados BB17092
Tel: 246-420-6795
Fax: 246-420-6797



​


LENSTEC UK

LENSTEC (BARBADOS) INC.
LENSTEC HOUSE
UNIT 8, MARINER House
CALDER PARK
WAKEFIELD

West Yorkshire wf4 3fl
ENGLAND
​
TEL: +44 (0)1924 382 678
FAX:+44 (0)1924 850 454
​


EUROPEAN REGIONAL OFFICE

TRENCIANSKA 47
821 09 BRATISLAVA
SLOVAK REPUBLIC

TEL: 00421905798760





​

​INDICATION 
The Lenstec Softec Aspheric Posterior Chamber Intraocular Lens is intended for the replacement of the human crystalline lens following phacoemulsification cataract removal in adults over the age of 21. The lens is indicated for capsular bag placement.
CAUTION: Federal (U.S.) law restricts some of these devices to the sale by or on the order of a physician.
Lenstec, Inc. is an ISO 13485 company manufacturing CE Marked Products with additional registrations of several countries.
​DUNS: 807554100
© 2021 Lenstec, Inc. All Rights Reserved. Lenstec, Softec, Softec HD, Tetraflex, SBL-3, and the Softec HD logo are registered trademarks of Lenstec, Inc.